Zealand Pharma Company Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.
It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome.
Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.
| Country | Denmark |
| Founded | 1997 |
| Industry | Other |
| Employees | 335 |
| CEO | Adam Steensberg |
Contact Details
Address: Sydmarken 11 Søborg, 2860 Denmark | |
| Phone | 45 88 77 36 00 |
| Website | zealandpharma.com |
Stock Details
| Ticker Symbol | ZLDPY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam Steensberg | Chief Executive Officer |
| Henriette Wennicke | Chief Financial Officer |
| Ivan Moller | Chief Operating Officer |